BioXcel Therapeutics

Update in progress

BTAI (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

BioXcel Therapeutics, Inc., with its subsidiary OnkosXcel, is a biopharmaceutical company using artificial intelligence to develop medicines in neuroscience and immuno-oncology in the United States. Its portfolio includes IGALMI for acute agitation in adults with schizophrenia or bipolar disorder, BXCL501 (an orally dissolving dexmedetomidine) in Phase 3 for agitation, BXCL701 (oral immune activator) in early trials for various cancers, and BXCL502–504 for dementia-related symptoms. Collaborations include Columbia, Yale, and UNC. Based in New Haven, CT.

Company score

Sentiment: 0.30; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.20; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.19; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive